Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High – Here’s What Happened

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) hit a new 52-week high on Tuesday . The stock traded as high as $59.94 and last traded at $59.60, with a volume of 447286 shares traded. The stock had previously closed at $57.13.

Analysts Set New Price Targets

A number of research firms have issued reports on KNSA. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Citigroup raised their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Monday, May 4th. Wedbush upped their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 29th. Finally, Canaccord Genuity Group raised their target price on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $60.86.

Kiniksa Pharmaceuticals International Price Performance

The firm has a 50-day simple moving average of $51.22 and a 200 day simple moving average of $46.49. The stock has a market capitalization of $4.57 billion, a P/E ratio of 65.93 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. During the same period in the previous year, the business posted $0.11 earnings per share. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. Sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.24 earnings per share for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 58,424 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the sale, the insider directly owned 65,623 shares of the company’s stock, valued at $3,524,611.33. The trade was a 47.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 1,703 shares of the firm’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $79,513.07. Following the transaction, the chief operating officer directly owned 12,029 shares of the company’s stock, valued at $561,634.01. The trade was a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 653,301 shares of company stock worth $34,046,073. Company insiders own 51.98% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KNSA. Mark Sheptoff Financial Planning LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock valued at $674,000 after buying an additional 250 shares during the period. Mariner LLC raised its position in shares of Kiniksa Pharmaceuticals International by 2.0% during the fourth quarter. Mariner LLC now owns 13,519 shares of the company’s stock worth $558,000 after acquiring an additional 266 shares during the last quarter. First Trust Advisors LP lifted its stake in shares of Kiniksa Pharmaceuticals International by 3.1% in the first quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock worth $476,000 after acquiring an additional 293 shares during the period. Virtus Investment Advisers LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 2.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock worth $678,000 after acquiring an additional 406 shares during the period. Finally, Mercer Global Advisors Inc. ADV boosted its holdings in Kiniksa Pharmaceuticals International by 7.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock valued at $317,000 after acquiring an additional 508 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.